Verma Hitesh, Garg Rajeev
IKG Punjab Technical University, Kapurthala, India.
Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, Punjab, India.
Endocr Metab Immune Disord Drug Targets. 2019;19(1):13-25. doi: 10.2174/1871530318666180703125007.
Multiple cross sectional and longitudinal studies reported the benefits of vitamin K intake for management of cardiometabolic risk factors so as to minimize the risk of cardiovascular diseases.
In present systematic review and meta-analysis, we aimed to evaluate the effect of vitamin K supplementation on cardiometabolic risk factors.
A systematic literature search of PubMed, Cochrane central, Clinicaltrials.gov, Google Scholar, Web of Science, EBSCO and Scopus databases was done from inception to November, 2017. A total of 13 trials were selected for inclusion into the present systematic review to evaluate the effect of vitamin K supplementation on cardiometabolic risk factors in healthy or in population at high risk of cardiovascular diseases.
Significant beneficial effects of vitamin K supplementation were found only in case of Creactive protein (p = 0.01) and insulin sensitivity index (p <0.001), while no significant effects of vitamin K supplementation were found in case of total cholesterol (p=0.857), low density lipoprotein - cholesterol (p=0.964), high density lipoprotein - cholesterol (p=0.998), interleukin - 6 (p=0.766), systolic blood pressure (p=0.660), diastolic blood pressure (p=0.818), fasting plasma glucose (p=0.362), fasting plasma insulin (p=0.928) and homeostasis model assessment for insulin resistance (p=0.672).
Presently available evidence are insufficient to ascertain the beneficial effects of vitamin K supplementation for the management of cardiometabolic risk factors. In order to explore the true potential of vitamin K supplementation for management of cardiometabolic diseases, large randomized placebo controlled trials are required in population with disturbed cardiometabolic profile. Present systematic review and meta-analysis is registered with PROSPERO (Registration number: CRD42018084608).
多项横断面研究和纵向研究报告了摄入维生素K对管理心血管代谢风险因素的益处,从而将心血管疾病风险降至最低。
在本系统评价和荟萃分析中,我们旨在评估补充维生素K对心血管代谢风险因素的影响。
对PubMed、Cochrane中心、Clinicaltrials.gov、谷歌学术、科学网、EBSCO和Scopus数据库进行了系统的文献检索,检索时间从数据库建立至2017年11月。共选择了13项试验纳入本系统评价,以评估补充维生素K对健康人群或心血管疾病高危人群心血管代谢风险因素的影响。
仅在C反应蛋白(p = 0.01)和胰岛素敏感性指数(p <0.001)方面发现补充维生素K有显著有益效果,而在总胆固醇(p = 0.857)、低密度脂蛋白胆固醇(p = 0.964)、高密度脂蛋白胆固醇(p = 0.998)、白细胞介素-6(p = 0.766)、收缩压(p = 0.660)、舒张压(p = 0.818)、空腹血糖(p = 0.362)、空腹血浆胰岛素(p = 0.928)和胰岛素抵抗稳态模型评估(p = 0.672)方面未发现补充维生素K有显著效果。
目前可得的证据不足以确定补充维生素K对管理心血管代谢风险因素的有益效果。为了探索补充维生素K对管理心血管代谢疾病的真正潜力,需要在心血管代谢状况紊乱的人群中进行大型随机安慰剂对照试验。本系统评价和荟萃分析已在国际前瞻性系统评价注册库(PROSPERO)注册(注册号:CRD42018084608)。